A 69-year-old man presented with a perirectal lesion and was found to have severe anemia in the course of evaluation.


Acute Myeloid Leukemia Myelodysplastic Syndrome Bone Marrow Biopsy Bone Marrow Aspirate Interstitial Deletion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Melchert M, Kale V, List A. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Curr Opin Hematol 2007;14:123–129.CrossRefPubMedGoogle Scholar
  2. 2.
    van den Berghe H, Michaux. 5q–, twenty-five years later: A synopsis. Cancer Genet Cytogenet 1997;94:1–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Hasserjian RP, Le Beau MM, List AF, et al. Myelodysplastic syndrome with isolated del(5q), In Swerdlow SH, Campo E, Harris NL, et al. eds., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2008, 102.Google Scholar
  4. 4.
    Giagoundidis AAN, Germing U, Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res 2006;12:5–10.CrossRefGoogle Scholar
  5. 5.
    Nimer SD. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol 2006;24:2576–2582.CrossRefPubMedGoogle Scholar
  6. 6.
    Kelaidi C, Eclache V, Fenaux P. The role of lenalidomide in the management of myelodysplasia with del 5q. Br J Haematol 2008;140:267–278.CrossRefPubMedGoogle Scholar
  7. 7.
    Nimer SD, Golde DW. The 5q– abnormality. Blood 1987;70:1705–1712.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Personalised recommendations